date:Jul 12, 2012
A Health Canada inspection of Building 86 at Sanofi Pasteur's manufacturing plant in Toronto found the presence of mould in the sterile manufacturing areas where ImmuCyst was produced.
Health Canada's review has concluded that ImmuCyst should remain available to bladder cancer patients, provided the drug continues to meet quality assurance standards. Samples from lots of ImmuCyst will be evaluated for quality by both the manufacturer and Health Canada before being released for use by Canadians.